• 1
    Pulford K, Lamant L, Morris SW, Butler LH, wood KM, Stroud D, Delsol G, Mason D. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 139402.
  • 2
    Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 96: 207684.
  • 3
    Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri S, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, et al. ALK expression defines a distinct group of T/Null lymphomas “ALK lymphomas” with a wide morphological spectrum. Am J Pathol 1998; 153: 87586.
  • 4
    Delsol G, Ralfkaier E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. Pathology and genetics. Tumors of haematopoietic and lymphoid tissues. International classification of tumours. Lyon: IARC Press, 2001. p 2305.
  • 5
    Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C, Mason DY. Immune response to the ALK oncogene tyrosine kinase in patients with anaplastic large cell lymphoma. Blood 2000; 96: 16057.
  • 6
    Borisch B, Yerly S, Cerato Ch, Schwaller J, Wacker P, Ozsahin HM, Brousse N, Hoessli D. ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions. Eur J Haematol 2003; 71: 2439.
  • 7
    Boon T, Old LJ. Cancer tumour antigens. Curr Opin Immunol 1997; 9: 6813.
  • 8
    Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 47605.
  • 9
    Brichard V, Van Pel A, Wolftel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma. J Exp Med 1993; 178: 48995.
  • 10
    Bakker AB, Screurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumour-infiltrating lymphocytes. J Exp Med 1994; 179: 10059.
  • 11
    Coulie PG, Brichard V, Van Pel A, Wolftel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP. A new gene coding for a differentiation antigen recognised by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 3542.
  • 12
    Wang RF, Appella E, Kawakami Y, Rosenberg SA. Identification of TRP-2 as a human tumour antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 220716.
  • 13
    Wang RF, Parkhurst MR, Kawakami Y, Kang X, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996; 183: 113140.
  • 14
    Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T-cell mediated immunity to chronic myelogenous leukemia. Oncogene 2002; 21: 866873.
  • 15
    Clark RE, Christmas SE. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma 2001; 42: 87180.
  • 16
    Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumour gene product WT1 and proteinase 3 in patients with acute myeloid leukaemia. Blood 2002; 100: 21327.
  • 17
    Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumour antigen: identification of 2 HLA-A2.1-restricted CD8+ T cell epitopes. Blood 2002; 99: 21006.
  • 18
    Palmowski M, Salio M, Dunbar RP, Cerundolo V. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev 2002; 188: 15563.
  • 19
    Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumour antigen for vaccination strategies. Leuk Lymphoma 2003; 44: 167581.
  • 20
    Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Jahka-Schaub G, Dorffel W, Zimmermann M, Mann G, Parwaresch R, Riehm H, Reiter A. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699706.
  • 21
    Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognise virus matrix protein in association with HLA-A2. Nature 1987; 326: 8812.
  • 22
    Parker KC, Bednarek MA, Hull LK, Utz U, Cunningham B, Zweerink HJ, Biddison WE, Coligan JE. Sequence motifs important for peptide binding to the human MHC Class I molecule, HLA-A2. J Immunol 1992; 149: 35807.
  • 23
    Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990; 345: 44952.
  • 24
    Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumour model. Vaccine 1997; 15: 38794.
  • 25
    Gricks CS, Rawlings E, Foroni L, Madrigal JA, Amlot PL. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex Class 1, providing a potential target for cytotoxic T cells. Cancer Res 2001; 61: 514552.
  • 26
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumour antigen. Cancer Res 2003; 63: 684855.
  • 27
    Dranoff G. Coordinated tumour immunity. J Clin Invest 2003; 111: 1168.
  • 28
    Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumours. Cancer Immunol Immunother 2003, 52: 7719.
  • 29
    Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3: 2216.
  • 30
    Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosine-related protein-2 (TRP-2). Cancer Res 1998; 58: 4895901.
  • 31
    Luckey CJ, King GM, Marto JA, Venketeswaran S, Maier BF, Crotzer VL, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 1998; 161: 11221.
  • 32
    Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000; 156: 171121.
  • 33
    Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumours. Am J Pathol 2000; 157: 37784.
  • 34
    Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 217588.
  • 35
    Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink HK, Seymour JF, Campbell LJ, Horsman DE, Auvigne I, Espinos E, Siebert R, et al. ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of six cases. Blood 2003; 102: 256871.
  • 36
    Li XQ, Hisaoka M, Shi DR, Zhu XZ, Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumours: an immunohistochemical and molecular study of 249 cases. Hum Pathol 2004; 35: 71121.
  • 37
    Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, et al. Induction of primary NY-ESO-1 immunity: Cd8% T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1% cancers. Proc Natl Acad Sci USA 2000: 97: 12198203.
  • 38
    Cerundolo V. Use of major histocompatibility complex class I tetramers to monitor tumor-specific cytotoxic T lymphocyte response in melanoma patients. Cancer Chem Pharmacol 2000; 46( Suppl): S835.
  • 39
    Morris EC, Bendle GM, Stauss HJ. Prospects for immunotherapy of malignant disease. Clin Exp Immunol 2003; 131: 17.
  • 40
    Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, et al. MAGE-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2:1% melanoma patients mature monocyte-derived dendritic cells. J Immunol 2000; 165: 34926.
  • 41
    Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 47784.
  • 42
    Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71: 1427.
  • 43
    Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT. Tumour escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 1996; 2: 64152.
  • 44
    Marincola FM, Jaffee EM, Hickun DJ, Ferrone S. Escape of human solid tumours from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 18173.
  • 45
    Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumour growth. Immunol Today 2000; 21: 45564.
  • 46
    Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, Blankenstein T. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumour growth and macrophage infiltration. Cancer Res 1993; 53: 41347.
  • 47
    Altenburger W, Suter GP, Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus. Arch Virol 1989; 105: 1527.
  • 48
    Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89: 1084751.
  • 49
    Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentralbl Bakteriol Hyg 1978; I167: 37590.
  • 50
    Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, Schneider J, Hannan C, Roy M, Gilbert SC, Peto TE, Hill AV. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21: 19952002.
  • 51
    Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R. Therapeutic vaccination with MCA E2 can eliminate pre-cancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15: 42131.
  • 52
    Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V. Recombinant modified Vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113: 25966.
  • 53
    Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 88627.
  • 54
    Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF. Generation of NY-ESO-1 specific CD4+ and CD8+ T cells by a single peptide with dual MHC Class I and Class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62: 36205.
  • 55
    Wagner WM, Quyang Q, Pawalwc G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother 2003; 52: 8996.